What does decrease in royalty financing obligations mean?

Measures the net change in the outstanding balance of liabilities structured against future royalty revenues. It reflects the company's ongoing repayment progress or the incurrence of new financing obligations tied to product performance.

BioCryst Pharmaceuticals BCRX Decrease in royalty financing obligations

Decrease in royalty financing obligations at other companies

BridgeBio PharmaBBIO

$871.19M+75.2%

BridgeBio PharmaBBIO

$11.29M+7,742%

Syndax PharmaceuticalsSNDX

$343.91M+3.7%

uniQureQURE

$482.33M+8.0%

MTD

Matador ResourcesMTDR

-$14M-143%

Bloom EnergyBE

$89K-80.3%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept bcrx:IncreaseDecreaseInRoyaltyFinancingLiabilities.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's decrease in royalty financing obligations.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's decrease in royalty financing obligations?: BioCryst Pharmaceuticals (BCRX) reported decrease in royalty financing obligations of -$8.47M in Q1 2026.
How has BioCryst Pharmaceuticals's decrease in royalty financing obligations changed year-over-year?: BioCryst Pharmaceuticals's decrease in royalty financing obligations increased by 41.8% year-over-year, from -$14.55M to -$8.47M.
What does decrease in royalty financing obligations mean?: Measures the net change in the outstanding balance of liabilities structured against future royalty revenues. It reflects the company's ongoing repayment progress or the incurrence of new financing obligations tied to product performance.